The germinal center (GC) reaction has a pivotal function in human B-cell lymphomagenesis. Genetic aberrations occurring during somatic hypermutation and class switch recombination deregulate key factors controlling B-cell physiology and proliferation. Several human lymphoma entities are characterized by a constitutive GC phenotype and ongoing somatic hypermutation, but the molecular basis for this phenomenon is only partly understood. We have investigated the reasons for a constitutive GC-like program in Burkitt's lymphoma cells. Here, overexpression of c-Myc leads to a centroblast phenotype, promotes high constitutive expression of the key GC factors Bcl-6, E2A and activation-induced cytidine deaminase and contributes to proliferation and somatic hypermutation. Our findings elucidate how the activity of a pivotal transcription factor may freeze B-cell lymphoma cells in a constitutive GC-like state that is even maintained at an extrafollicular location.
Introduction
During acute infections, the passage of human B cells through the germinal center (GC) has a fundamental function in the establishment of effective humoral immunity. In the GC, antigen-specific B cells undergo intense proliferation and alter their immunoglobulin (Ig) genes by somatic hypermutation and class switch recombination (Rajewsky, 1996) . Activation-induced cytidine deaminase (AID) initiates both processes by transcription-coupled deamination of cytidines in Ig genes (Honjo et al., 2002; Di Noia and Neuberger, 2007) . GC B cells are characterized by a unique transcription program distinct from other B-cell subsets (Shaffer et al., 2001) . The high expression of key transcription factors such as Bcl-6 and E2A contributes to the particular phenotype and genetic processes characterizing these cells.
Both somatic hypermutation and class switch recombination may lead to genetic aberrations promoting lymphomagenesis (Kuppers et al., 1999) . Hypermutation is not completely specific for Ig genes, but also modifies other highly transcribed genes in normal GC cells, for example bcl-6 (Pasqualucci et al., 1998; Shen et al., 1998) . Diffuse large B-cell lymphoma (DLCL) is characterized by mutations in multiple genes, and this phenomenon termed as aberrant hypermutation (Pasqualucci et al., 2001) has also been observed in other entities. Somatic hypermutation and class switch recombination may also lead to chromosomal translocations that deregulate key molecules affecting B-cell proliferation and physiology. Prototypic examples include the frequent translocation of bcl-6 in DLCL as well as the translocation of the c-myc gene into the Ig locus in Burkitt's lymphoma (BL) (Kuppers and DallaFavera, 2001 ). Presumably because of the frequency of such genetic alterations, most lymphoma entities in the human are derived from GC B cells or their descendants (Kuppers et al., 1999) .
Several human lymphoma entities are also characterized by a constitutive GC phenotype judged by expression of specific surface markers such as CD77, as well as critical GC factors as Bcl-6, AID or E2A (that already has a function in early B-cell development, but is particularly highly expressed in GC centroblasts). These entities include BL, the GC-like subtype of DLCL and follicular lymphoma, among others. In addition, some of these lymphomas show constitutive somatic hypermutation that may contribute to further genetic instability of the cells. The molecular mechanisms leading to these phenomena are only partly understood. It is often assumed that the phenotype of a B-cell lymphoma entity reflects the cell of origin of the malignant clone (Kuppers et al., 1999) . In case of DLCL, though, aberrant expression of Bcl-6 may directly inhibit differentiation of the cells to plasma cells and hence contribute to maintenance of the GC phenotype (Cattoretti et al., 2005) . In case of other lymphoma entities, mechanisms leading to a constitutive GC physiology and ongoing somatic hypermutation remain to be elucidated.
BL is the prototype of a GC-like lymphoma entity. The malignant cells are characterized by high expression of the GC/centroblast marker CD77 (formerly known as Burkitt lymphoma antigen) by rapid proliferation and frequently by constitutive somatic hypermutation (Chapman et al., 1998) . Analysis of the rearranged Ig genes also implies that BL cells are derived from GC cells or their descendants (Klein et al., 1995) . The hallmark of the disease is the translocation of the c-myc proto-oncogene into the Ig loci as a result of inappropriate class switch recombination or somatic hypermutation (Dalla-Favera et al., 1982) . The impact of Ig enhancer elements leads to c-Myc overexpression, and in addition, targets somatic hypermutation to the translocated c-myc gene, further exacerbating its deregulation (Johnston et al., 1991) . BL cells are thus characterized by rapid but mostly extrafollicular growth.
The contribution of c-Myc overexpression to the phenotype of BL cells is only partly understood. The proto-oncogene c-Myc affects the expression of many cellular genes at the level of transcription as well as posttranscriptionally Cole and Cowling, 2008) . Among these c-Myc targets, regulators of cell metabolism, cell-cycle control and proliferation are prominent. Mouse models of c-Myc overexpression in B cells have also shown that its deregulation strongly promotes lymphomagenesis (Adams et al., 1985; Kovalchuk et al., 2000; Chesi et al., 2008) . Most existing models, though, do not show the characteristic GC-like phenotype of BL cells or even ongoing somatic hypermutation. Rather, c-Myc overexpression in B-cell progenitors or naive B cells leads to lymphoma cells of the respective differentiation stage (Adams et al., 1985; Kovalchuk et al., 2000) . Deregulation of c-Myc at later stages of B-cell development mostly leads to plasmacytoma models in the mouse (Adams et al., 1983; Chesi et al., 2008) , with one notable exception that relies on constitutive autoantigenic stimulation (Refaeli et al., 2008) . Accordingly, the contribution of c-Myc to a GC-like physiology of human BL tumors is unclear at present.
Moreover, the function of c-Myc in normal GC B cells is a matter of debate. Although earlier studies showed high c-Myc expression in the GC, more recent data revealed that c-Myc expression and activity in GC B cells are rather uncharacteristically low (MartinezValdez et al., 1996; Shaffer et al., 2001; Klein et al., 2003) . In vitro models of BL pathogenesis have shown, though, that c-Myc overexpression in B cells may induce some features that are also found in GC B cells (Polack et al., 1996; Pajic et al., 2001) .
In this study, we have investigated potential reasons for a constitutive GC phenotype and somatic hypermutation in BL cells. We show that c-Myc overexpression induces the centroblast-like phenotype of the cells, promotes expression of the key GC factors Bcl-6, E2A and AID and also contributes to ongoing somatic hypermutation in the cells. These characteristic features of human BL cells may thus be indicative of the high activity of the oncogenic transcription factor c-Myc, rather than pointing to the differentiation state of the cell of origin of the tumor clone.
Results
We used an episomally replicating reporter system to measure hypermutation capacity of human B-cell lines (Figure 1a) . The vector contains a CMV-promoterdriven GFP gene with a premature stop codon, the reversion of which during somatic hypermutation leads to GFP þ cells that are detectable by FACS (Bachl and Olsson, 1999; Yoshikawa et al., 2002) . Hypermutation on this reporter is increased by Igk enhancer elements that have earlier been shown to confer Ig locus control (Polack et al., 1993) . The reporter used differs from an earlier published system that has been developed and confirmed to measure somatic hypermutation in human cells (Ruckerl et al., 2006) by an improved SV40-promoter-driven hygromycin resistance cassette allowing its application to more cell lines.
With this system, the hypermutation capacity of a panel of adequately transfectable and selectable human B-cell lines was studied. All hypermutating lines were derived from BL, whereas non-mutating cell lines were BL, BL-like and lymphoblastoid cell lines (Table 1) . Representative assays for some lines are shown in Figure 1b . The hypermutation capacity of individual lines differed between batches, apparently because of the earlier described counterselection of AID high cells during culture (Zhang et al., 2001) . Despite variations in its rate, though, hypermutation potential of the lines could be easily classified on the basis of a constant increase of GFP þ cells in the culture. To find potential reasons for constitutive hypermutation activity of the BL lines, we characterized their phenotype as well as expression of critical GC factors at the RNA and protein level. On average, the expression of AID RNA was higher in hypermutating than in nonmutating lines, although prediction of hypermutation capacity solely on the basis of AID mRNA expression seemed impossible (Figure 1c ). At the AID protein level, differences between mutating and non-mutating cells were more evident, but AID expression was also clearly detectable in some non-mutating cell lines (Figure 1d) . For none of the tested GC transcription factors (Bcl-6, E2A, Pax-5), a correlation of RNA or protein levels to hypermutation potential of the cell lines was seen (data not shown). We also assessed the GC phenotype of the cell lines, using the prototypic markers CD38 and CD77. To our surprise, we noticed that all BL lines harbored CD77-negative cells, and some even entirely lacked cells with a CD77 þ centroblast-like phenotype. In vivo, most but not all BL cases are CD77 positive (Aiello et al., 1990) , but this phenotype might also be affected during in vitro culture. Notably, the presence of CD77-positive cells in a cell line proved to be the best predictor of its hypermutation capacity ( Figure 1e ; Table 2 ). The single exception to this rule was an in vitro transformed model BL-like cell line (P4936) on the basis of overexpressing c-Myc in naive B cells, which comprises a CD77-positive population (Figure 2a ), but does not show detectable hypermutation activity.
In the cell system from which the P4936 cell line is derived, c-Myc overexpression has earlier been shown to c-Myc and the germinal center program in BL H Scheller et al induce some markers that are also found on GC cells but are negatively affected by EBV latent genes (Polack et al., 1996; Pajic et al., 2001) . We, therefore, assessed whether c-Myc overexpression is also capable of inducing expression of the centroblast marker CD77. This is indeed the case. Although the parental conditionally EBV-transformed EREB2-5 cell line is negative for CD77, the derivative constitutively c-Myc overexpressing A1 cells are clearly positive (Figure 2a ). P4936 cells in which c-Myc overexpression is driven by a tetracycline-repressible promoter show a CD77-positive population in the presence of c-Myc, but are negative in its absence.
To investigate how c-Myc may contribute to the expression of GC-like features in B cells, we assessed its 
c-Myc and the germinal center program in BL H Scheller et al ability to transcriptionally induce critical GC factors by performing a kinetics experiment in P4936. Interestingly, bcl-6 RNA levels increased sharply, but only transiently on c-Myc induction ( Figure 2b , left panel), whereas RNA levels for AID changed only moderately and in a complex manner, and levels of E2A (and Pax-5, data not shown) barely varied. We conclude that c-Myc overexpression does not affect the GC program by persistent transcriptional induction of any of the key factors investigated. As c-Myc may also influence protein expression of some of its targets through interference with posttranscriptional processes, we assessed the protein levels of the GC factors under study. Indeed, protein levels of E2A and AID were substantially higher in P4936 cells overexpressing c-Myc than in their c-Myc-negative counterparts (Figure 2c) . Although Bcl-6 protein levels were at the detection limit of the antibody, they seemed to be similarly affected (see lower band in Figure 2c , compare also with Figure 3b) . Levels of the B-cellspecific transcription factor Pax-5, however, remained unchanged. The effect of c-Myc on protein levels is due to a slow cellular process, as establishment of the observed differences in protein levels was detected only 3-5 days after switching off c-Myc overexpression. Thus, c-Myc upregulation affects the expression of critical GC factors in P4936 cells post-transcriptionally, for example by interference with translation or protein turnover.
To assess the influence of c-Myc overexpression in BL cells, we made use of a chemical inhibitor of c-Myc function (Calbiochem 475956) that specifically interferes with Myc/Max interaction (Yin et al., 2003) . As observed in the P4936 system, c-Myc inhibition led to a decrease in CD77 positivity in BL cell lines (Figure 3a) . Concomitantly, the protein levels of Bcl-6, E2A and to a lesser extent AID were reduced (Figure 3b ). This could only in part be explained by changes in mRNA levels (Figure 3c ), suggesting again that c-Myc affects post-transcriptional processes regulating protein expression of critical GC factors.
We had shown before that both the c-Myc-induced positivity of BL cells for CD77 as well as AID expression levels correlated with their hypermutation capacity (Figure 1 ). In addition, c-Myc influenced AID expression at the level of transcription as well as apparently post-transcriptionally. We reasoned that the effects of c-Myc on AID might in part be due to c-Myc effects on other GC transcription factors that regulate the expression of AID. To assess which of the factors investigated are responsible for constitutive AID expression in hypermutating BL cells, we used vectormediated RNA interference. An episomally replicating vector system with a U6-promoter-driven shRNA expression cassette and an independent cassette for expression of a truncated nerve growth factor receptor (ngfr t ) was constructed (Figure 4a) , and 2-3 independent shRNAs targeting each of the transcription factors investigated were inserted. Three days after transfection into Raji BL cells, vector-containing cells were isolated by magnet-assisted cell sorting using their ngfr t surface expression and compared at the protein and RNA level. c-Myc downregulation was only partially successful in this approach (and even less so in attempts of prolonged inhibition, not shown), likely because of the very high level of its overexpression in BL cells and its requirement for their proliferation (Figure 4b ). As c-Myc effects on protein levels of GC factors required 3-5 days even on full c-Myc inhibition, no substantial impact was expected. Downregulation of Bcl-6, E2A and Pax5, however, was more efficient. Notably, the decrease in phenotype and the expression of the critical GC factors Bcl-6, E2A and AID, but also the proliferation and somatic hypermutation activity of the cells.
Discussion
In this study, we show that c-Myc overexpression in BL cells contributes to some of the most characteristic features of this lymphoma entity: a centroblast-like phenotype, high expression of the critical GC factors Bcl-6, E2A and AID, as well as constitutive proliferation and somatic hypermutation activity. We have seen these c-Myc effects in a conditionally transformed cell line derived from naive B cells as well as in BL cells that have passed a GC reaction before their malignant transformation, suggesting that the regulatory mechanisms at play may be generally active in the human B-cell lineage. However, concerning the biological impact of c-Myc overexpression, effects occurring in B cells at different developmental stages have to be differentiated. Although high c-Myc overexpression in P4936 cells precipitates expression of GC surface markers and higher Bcl-6, E2A and AID protein amounts, absolute levels are substantially lower than in BL cells and somatic hypermutation is not induced. The latter may require a certain threshold of AID expression and potentially other conditions. However, aberrant c-Myc induction in (post)GC cells predisposed to expression of such critical factors may raise their levels to an extent that precipitates a constitutive GC program and somatic hypermutation. This scenario is consistent with the observation that c-Myc overexpression in pre-GC cells in the mouse does not lead to GC-like tumors (Adams et al., 1985; Kovalchuk et al., 2000) . In addition, one may speculate that the danger of aberrant maintenance of a GC program by c-Myc (over)expression explains the low activity of c-Myc in normal human GC cells (Shaffer et al., 2001; Klein et al., 2003) , potentially as a prerequisite for rapid regulation of GC factors on cessation of the GC response. It will be interesting to investigate the impact of c-Myc overexpression on the kinetics of the GC response in a mouse model (Khuda et al., 2008) , although it remains to be seen whether the mechanisms leading to deregulation of Bcl-6, E2A and AID on c-Myc overexpression are applicable to the murine situation. Indeed, c-Myc expression in mouse GCs deserves investigation, as here the c-Myc gene is strongly targeted by AID, and its transcription would be a prerequisite for this to occur (Liu et al., 2008) . The above facts also need to be considered when discussing whether human BL cells are derived from GC or post-GC (for example, memory) cells (Klein et al., 1998; Thorley-Lawson and Allday, 2008) . According to our data, a GC origin may seem more likely as deregulation of the highly expressed GC factors is more easily feasible, but we anticipate that their expression in post-GC cells may also be high under certain conditions, as has recently been shown for AID on escape from its cognate miRNA control (Teng et al., 2008) .
We have seen that c-Myc overexpression leads to a strong transcriptional induction of the bcl-6 gene. The bcl-6 promoter contains multiple E-boxes that are also bound by the c-Myc antagonist Mad (Lee et al., 2006) . However, in the P4936 system, c-Myc-driven induction of bcl-6 transcription is only transient, so it is presently unclear whether transcriptional induction of bcl-6 by c-Myc contributes to Bcl-6 deregulation in lymphomagenesis, for example in cells in which autoregulation of bcl-6 transcription is defunct (Pasqualucci et al., 2003) . In fact, c-Myc and Bcl-6 are rarely coexpressed in DLCL (Wagner et al., 2007) . The effects of c-Myc on AID transcription are also interesting, but the pattern is complex, likely indicative of multiple regulatory processes. Indeed, c-Myc has been shown to interfere with several factors that are known to regulate AID transcription, for example NfkB and E2A (Sayegh et al., 2003; Dedeoglu et al., 2004) . Accordingly, the impact of c-Myc on AID transcription may differ depending on the cellular context. In this study, we have focussed on the final protein levels of critical GC factors, as we wished to identify mechanisms responsible for a constitutive GC program in BL cells. c-Myc overexpression leads to high protein levels of Bcl-6, E2A and AID, apparently also by posttranscriptional mechanisms. c-Myc interferes with translational efficiency (Cole and Cowling, 2008) , and it can also alter pathways of protein degradation in a cell (Gavioli et al., 2001) . All three factors affected by c-Myc overexpression in this study are targets of proteasomal degradation, but whether and how c-Myc affects their protein turnover remains to be studied. Indeed, c-Myc may exert its effects directly or indirectly, and multiple factors or mechanisms may be responsible for the final levels of the GC factors investigated, so we anticipate substantial interplay and crossregulation. In defined cases, a detailed elucidation of the responsible mechanism(s) may be justified, given the potential impact on the biological function of the affected GC factors discussed below.
Bcl-6 is often considered the master switch of the GC reaction, as it is required for GC formation and somatic hypermutation (Toyama et al., 2002) and prevents the differentiation of GC cells to plasma cells. Bcl-6 is highly expressed in centroblasts and may be downregulated in differentiating centrocytes by NfkB-mediated processes or a strong B-cell receptor signal (Niu et al., 1998; Saito et al., 2007) . c-Myc overexpression in GC-like BL cells may interfere with this regulation and thus contribute to maintenance of the GC phenotype. It will be interesting to see whether interference with c-Myc function in BL cells facilitates their differentiation and thus removal from the malignant pool.
c-Myc-mediated regulation of E2A as a major regulator of Ig transcription may even contribute to overexpression of the translocated c-Myc gene itself, which is under control of Ig enhancer elements. Such a positive feedback loop may substantially impact on BL pathogenesis. Indeed, we have observed a decrease in cMyc protein levels on chemical inhibition of c-Myc in BL cells, but not in the P4936 cell line, an observation that deserves further investigation. In addition, E2A regulation by c-Myc is notable with respect to its high expression in centroblasts (Rutherford and LeBrun, 1998 ) as well as its described function in somatic hypermutation (Schoetz et al., 2006) .
In this context, the effects of c-Myc on AID protein levels are of particular importance. We have shown by RNA interference that multiple transcription factors are responsible for constitutive AID expression in BL cells, consistent with the described complexity of AID regulation. c-Myc overexpression induces high expression of several factors that affect AID levels and depending on the basal cellular context on which c-Myc acts, the final AID levels may or may not be sufficient to induce constitutive somatic hypermutation. Our data do not allow to differentiate whether interference with somatic hypermutation on c-Myc inhibition is due to an impairment with the mutational machinery or with proliferation or both, a question that is also complicated by the fact that hypermutation is traditionally quantified relative to cell generations even though evidence for mutagenesis in G1 as well as proliferation-independent mutagenesis have been provided (Faili et al., 2002; Wang and Wabl, 2005) .
In any case, though, c-Myc overexpression is required for ongoing somatic hypermutation in BL cells and may apparently also promote hypermutation of the translocated c-Myc gene itself, further contributing to c-Myc deregulation during BL pathogenesis. Alterations in c-Myc activity because of mutations in individual cells of the malignant clone may also impact on other aspects of tumor physiology. It will thus be interesting to investigate how variations in c-Myc activity caused by endogenous mutagenesis or by exogenous therapeutic approaches in BL cells impact on the behavior of the cells and may potentially be exploited for milder therapy options for this lymphoma entity.
Materials and methods

Vectors
The promoter in front of the hygromycin resistance gene in the published pEpi hypermutation reporter (Ruckerl et al., 2006) was exchanged for a SV40 promoter using the SgrA1 and Cpo1 restriction sites in pEpi and pBB230. For cloning of the shRNA vectors, the corresponding F and R oligonucleotides (see Table 2 ) were annealed and cloned into the pBJ3*-PincU6-ngfr vector cut with Pml1 and Xho1.
Cell culture All cell lines were cultured in RPMI-1640 (Invitrogen, Karlsruhe, Germany) containing 10% fetal bovine serum, penicillin, streptomycin, sodium pyruvat and glutamine at 37 1C in a humidified 5% CO 2 atmosphere. The EREB2-5 line was cultured in the presence of 2 mM estrogen. For inactivation of the exogenous c-Myc in the P4936 line, cells were cultured in the presence of 1 mg/ml tetracycline. For kinetics of c-Myc induction, cells treated with tetracycline were washed twice in medium and incubated in the absence of tetracycline for the indicated time points. Treatments with the c-Myc inhibitor (Calbiochem, San Diego, CA, USA, Cat. Nr. 475956) were performed at a concentration of 64 mM unless indicated otherwise, and a viability of the cells of >60% was retained even after prolonged treatments for 5 days.
Somatic hypermutation assays and FACS analyses
Three to four days after electroporation of 2 Â 10 7 cells with 10 mg of the hypermutation reporter, selection was started by addition of 50-400 mg/ml hygromycin (Invitrogen) and was typically complete 14 days after transfection (as determined c-Myc and the germinal center program in BL H Scheller et al with a GFP þ control vector). Every 2-4 days, about 10 6 living cells were analyzed for GFP þ cells on an FACScan (Becton Dickenson, Heidelberg, Germany). At least two independent experiments were carried out for each sample and representative data are shown. Copy numbers of the reporter were determined as before (Mierau et al., 2008) , but no normalization of hypermutation data to reporter copy numbers was performed as only qualitative assessments of hypermutation potential were required and copy numbers approached one copy per cell toward the end of most hypermutation experiments. For quantitative comparisons in hypermutation assays using a c-Myc inhibitor, the culture was split after completion of selection and aliquots were continuously treated with the inhibitor. For determination of cell proliferation, dilutions with fresh medium were performed identically for all aliquots, and viable cells were counted on all days of FACS analysis. Staining for surface marker expression used anti-CD77-FITC (BD Pharmingen Biosciences, San Diego, CA, USA) and antihuman CD38-PE (BD Pharmingen Biosciences). FACS data were analyzed with Cellquest software, gating for viable cells through scatter analyses and propidium iodide exclusion.
RNA interference and quantification of gene expression A total of 2 Â 10 7 cells were transfected with the respective RNAi vector and cultured for 3 days. Vector-bearing cells were then isolated by magnet-assisted cell sorting using a mouse anti-ngfr antibody (derived from the ATCC HB-8737 cell line) and anti-mouse magnetic beads (Milteny Biotec, Bergisch Gladbach, Germany).
For western blot analyses, cells were dissolved directly in 2 Â laemmli sample buffer before proteins were dissolved by SDS-PAGE and transferred to PVDF membranes. The following antibodies were used for detection: anti-AID
